Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06319820 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

A Phase 3 study of Non-Muscle Invasive Bladder Neoplasms, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 3
Development phase
641
Enrollment target
20
Study locations

NCT06319820 is a Phase 3 study of Non-Muscle Invasive Bladder Neoplasms that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 641 participants, above the 207-participant average among 6 other Non-Muscle Invasive Bladder Neoplasms trials with a reported enrollment target (210% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06319820, a Phase 3 study of Non-Muscle Invasive Bladder Neoplasms, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 3
Development phase
641 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

Conditions Studied

Non-Muscle Invasive Bladder Neoplasms

Interventions

  • DRUG Gemcitabine
  • COMBINATION_PRODUCT TAR-210
  • DRUG MMC

Study Locations (20)

California

  • Genesis Research LLC - Los Alamitos
  • USC Norris Comprehensive Cancer Center - Los Angeles
  • University of California Irvine Medical Center - Orange
  • Om Research LLC - San Diego
  • Genesis Research LLC - Sherman Oaks

Colorado

  • University of Colorado Cancer Center Anschultz Cancer Pavilion - Aurora
  • Colorado Clinical Research - Lakewood

Michigan

  • Karmanos Cancer Institute - Detroit
  • Comprehensive Urology - Royal Oak

Missouri

  • Mercy Research - St Louis
  • Specialty Clinical Research of St Louis - St Louis

Arkansas

  • Arkansas Urology - Little Rock

Florida

  • Moffitt Cancer Center - Tampa

Illinois

  • Northwestern University - Chicago

Indiana

  • First Urology - Jeffersonville

Trial Details

FieldValue
Enrollment Target 641 participants
Start Date 2024-04-18
Est. Completion 2032-12-31
Phase Phase 3

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06319820

The ClinicalTrials.gov registry entry for NCT06319820 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 641 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 207-participant average among 6 other Non-Muscle Invasive Bladder Neoplasms trials with a reported enrollment target (210% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Muscle Invasive Bladder Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.

NCT06319820 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Colorado, Michigan.

Frequently Asked Questions

What is clinical trial NCT06319820 about?

NCT06319820 is a clinical study titled "A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer". The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

What is the current status of trial NCT06319820?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 641 participants. The study started on 2024-04-18. Estimated completion is 2032-12-31.

What conditions does trial NCT06319820 study?

This clinical trial studies the following conditions: Non-Muscle Invasive Bladder Neoplasms.

What interventions are being tested in trial NCT06319820?

The interventions under investigation include: Gemcitabine (DRUG), TAR-210 (COMBINATION_PRODUCT), MMC (DRUG).

Who is sponsoring clinical trial NCT06319820?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06319820 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Muscle Invasive Bladder Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Muscle Invasive Bladder Neoplasms

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.